Member Info for Wiggly

For those that were enjoying a trade elsewhere...

The cat is out of the bag.

MASS POPULATION SCREENING.

Very close now.

1.515 to sell full holding.

The risk vs reward ratio is improving exponentially, week by week.

From this point, I struggle to see how AVCT would fail to return substantial returns to its shareholders.

Very much my belief that this is a once in a life time opportunity.

I currently only hold AVCT as I cannot see how any other share/fund will outperform over the coming 6, 12, 24 months.

It now says PATENT PENDING

Medusa is linked to our joint broker Zeus Capital.

They should tread carefully.

Beginning to damage avct reputation. Shame as Dr Al does an immense job in promoting the company.

Either it's information released in error OR Medusa are playing games. The final paragraph clearly relates to PCR/ANTIGEN testing and not antibody testing..

If medusa are playing games I'd question whether this is a partner we wish to work with.

Comparable results with a PCR test for asymptomatic patients but without significant discomfort from throat and nasal swab and considerable delay in results.

94% sensitivity, 95% specificity and 95% accurate

Sorry, but how does the above relate to Antibody testing?

I recall during the Webinar that S&S was debated and described as being a trade off. To achieve higher sensitivity we would need to give on specificity and vica versa.

This is our 'Exclusive' partner. AVCT need to urgently update the market.

Has anyone heard from investor relations?

Agree. Hope its true however we need rns!!!

Wow

NEW – Medusa 19 Life Sciences Rapid Saliva Protein Test

Medusa 19 are working with their partner, Medusa 19 Life Sciences, to exclusively bring to market the best in class saliva lateral flow test for early detection of SARS-CoV-2 proteins and highly accurate in identifying the virus in asymptomatic patients.

The Rapid Saliva Protein Test (RSPT) is a simple, non-invasive, on the spot test indicating infection from SARS-CoV-2, the virus underlying COVID-19.

It is a lateral flow test requiring a simple saliva sample, a comfortable and non-invasive collection process, providing rapid results within 10 minutes.

Comparable results with a PCR test for asymptomatic patients but without significant discomfort from throat and nasal swap and considerable delay in results.

94% sensitivity, 95% specificity and 95% accurate

It's chalk and cheese imo.

No chance can Integumen generate anything close to the revenues AVCT are likely to achieve.

149.5..... / 152

Hold tight!

If its NT to purchase GBP 1000, does that suggest Milton are out?

tick tick tick

Assault on 150 coming up

Don't understanding selling at this point in the journey though.

Milton have no choice …. and the fact that they have no choice is creating a once in a lifetime investment opportunity for everyone else.

I have no doubt that as soon as they are cleared (pressure is building today, which suggests they perhaps are) that this will break upwards quite significantly.

The only doubt regarding my investment here was the fact each recent rise was sold into, despite the news being hugely favourable for AVCT IMO!

My best guess was a distressed seller, as I truly believe fair value at this juncture is many multiples of 1.43.

With Milton out I predict a rapid move back to all time highs.